Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program
- PMID: 28945865
- DOI: 10.1093/annonc/mdx404
Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program
Abstract
Background: EGFR mutations cause inconsistent response to EGFR tyrosine-kinase inhibitors (TKI). To better understand these features, we reviewed all cases of EGFR-mutated non-small-cell lung cancer collected in the Biomarkers France database.
Patients and methods: Of 17 664 patients, 1837 (11%) with EGFR-mutated non-small-cell lung cancer were retrospectively analyzed for clinical and molecular characteristics. Results were correlated with survival and treatment response for the 848 stage IV patients.
Results: EGFR exon 18, 19, 20 and 21 mutations were found in 102 (5.5%), 931 (51%), 102 (5.5%) and 702 (38%) patients, respectively. Over 50% of exon 18 and 20 mutated patients were smokers. The median follow-up was 51.7 months. EGFR mutation type was prognostic of overall survival (OS) versus wild-type {exon 19: hazard ratio (HR)=0.51 [95% confidence interval (CI): 0.41-0.64], P < 0.0001; exon 21: HR = 0.76 (95% CI: 0.61-0.95), P = 0.002; exon 20: HR = 1.56 (95% CI: 1.02-2.38), P = 0.004}. EGFR mutation type was prognostic of progression-free survival versus wild-type [exon 19: HR = 0.62 (95% CI: 0.49-0.78), P < 0.0001; exon 20: HR = 1.46 (95% CI: 0.96-2.21), P = 0.07]. First-line treatment choice did not influence OS in multivariate analysis. First-line TKI predicted improved progression-free survival versus chemotherapy [HR = 0.67 (95% CI: 0.53-0.85), P = 0.001]. OS was longer for del19 versus L858R, which was associated with better OS compared with other exon 21 mutations, including L861Q. TKI improved survival in patients with exon 18 mutations, while chemotherapy was more beneficial for exon 20-mutated patients.
Conclusion: EGFR mutation type can inform the most appropriate treatment. Therapeutic schedule had no impact on OS in our study, although TKI should be prescribed in first-line considering the risk of missing the opportunity to use this treatment.
Keywords: epidemiology; epidermal growth factor receptor gene (EGFR) mutations; non-small-cell lung cancer (NSCLC); tyrosine-kinase inhibitors (TKI).
© The Author 2017. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Similar articles
-
Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) biomarkers France project.Lung Cancer. 2020 Feb;140:19-26. doi: 10.1016/j.lungcan.2019.10.013. Epub 2019 Nov 15. Lung Cancer. 2020. PMID: 31841714
-
Clinical predictors of response to EGFR-tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer: A real-world multicentric cohort analysis from India.Curr Probl Cancer. 2020 Jun;44(3):100570. doi: 10.1016/j.currproblcancer.2020.100570. Epub 2020 Mar 20. Curr Probl Cancer. 2020. PMID: 32498966
-
Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.Eur J Cancer. 2019 Sep;119:77-86. doi: 10.1016/j.ejca.2019.06.025. Epub 2019 Aug 16. Eur J Cancer. 2019. PMID: 31425965
-
Overall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung cancers: a systematic review and meta-analysis.Br J Cancer. 2015 Nov 17;113(10):1519-28. doi: 10.1038/bjc.2015.356. Epub 2015 Oct 13. Br J Cancer. 2015. PMID: 26461059 Free PMC article. Review.
-
[Afatinib as first-line therapy in mutation-positive EGFR. Results by type of mutation].Med Clin (Barc). 2016 Apr;146 Suppl 1:12-8. doi: 10.1016/S0025-7753(16)30258-5. Med Clin (Barc). 2016. PMID: 27426243 Review. Spanish.
Cited by
-
Uncommon EGFR mutations in lung carcinoma: features and treatment outcomes in a retrospective French cohort.J Thorac Dis. 2022 Jun;14(6):2034-2044. doi: 10.21037/jtd-21-1924. J Thorac Dis. 2022. PMID: 35813741 Free PMC article.
-
PET radiomics in lung cancer: advances and translational challenges.EJNMMI Phys. 2024 Oct 3;11(1):81. doi: 10.1186/s40658-024-00685-5. EJNMMI Phys. 2024. PMID: 39361110 Free PMC article. Review.
-
Translating Systems Medicine Into Clinical Practice: Examples From Pulmonary Medicine With Genetic Disorders, Infections, Inflammations, Cancer Genesis, and Treatment Implication of Molecular Alterations in Non-small-cell Lung Cancers and Personalized Medicine.Front Med (Lausanne). 2019 Oct 29;6:233. doi: 10.3389/fmed.2019.00233. eCollection 2019. Front Med (Lausanne). 2019. PMID: 31737634 Free PMC article. Review.
-
Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario.Int J Mol Sci. 2019 Mar 21;20(6):1431. doi: 10.3390/ijms20061431. Int J Mol Sci. 2019. PMID: 30901844 Free PMC article. Review.
-
EGFR Exon 18 Mutations in Advanced Non-Small Cell Lung Cancer: A Real-World Study on Diverse Treatment Patterns and Clinical Outcomes.Front Oncol. 2021 Sep 2;11:713483. doi: 10.3389/fonc.2021.713483. eCollection 2021. Front Oncol. 2021. PMID: 34540680 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous